New Tau Type Found in Nerves: What MS Patients Need

Credibility

Interest

Share:2 min read

Key Takeaway

Researchers found a long form of the protein tau, called “big tau,” is common in peripheral nerves but rare in the brain and does not rise with Alzheimer’s changes in cerebrospinal fluid.

What They Found

Tau is a protein that can change shape and build up in nerve diseases; scientists looked for a long version called big tau that includes an extra piece of code (exon 4a). Big tau comes in two lengths (one 355 and one 251 building-blocks long) and is made in several slightly different forms, like having different colored beads on the same string. The total amount of tau is much higher in the brain than in peripheral nerves, but big tau makes up about half of the tau in peripheral nerves and only about 1% in the brain, mostly in the cerebellum (a brain area that helps balance and coordination). In spinal fluid taken from around the brain, levels of big tau did not change with signs of Alzheimer’s disease or with thinking problems, while the usual short tau did go up with Alzheimer’s changes. This shows big tau is a separate group of tau proteins that is more linked to the peripheral nervous system than to the brain changes seen in Alzheimer’s disease.

Who Should Care and Why

MS patients and caregivers should care because MS can affect both the central nervous system (brain and spinal cord) and the peripheral nerves, and this study shows a specific tau type is mainly in the peripheral nerves. Knowing big tau is different from the usual brain tau is like knowing there are two different warning lights on a car dashboard — one for engine trouble and one for the tires — and they mean different things. Doctors and researchers who measure tau in spinal fluid may use this information to better tell whether a problem comes from the brain (like Alzheimer’s) or from peripheral nerves. Caregivers might find it helpful because it suggests some tests that look at tau may not reflect peripheral nerve damage, so symptoms like numbness or weakness from nerve problems might need different tests. Overall, this could help healthcare teams choose better tests and avoid misreading spinal fluid results when deciding on treatments or follow-up for MS-related nerve issues.

Important Considerations

This study used samples from donated bodies after death and spinal fluid from people studied for dementia, so results may not exactly match living MS patients with active symptoms. It does not prove big tau causes symptoms or disease; it just maps where big tau is and how it behaves in tests. Because the work focused on Alzheimer’s and controls, more research is needed to know how big tau behaves in MS specifically before changing care plans.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Genetics MS Diagnostics

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News